替瑞奇珠单抗与司库奇尤单抗治疗中重度斑块状银屑病的疗效和安全性对比

打开文本图片集

中图分类号 R969.4；R758.63 文献标志码A 文章编号 1001-0408（2026）07-0933-05

DOI 10.6039/j.issn.1001-0408.2026.07.18

Comparisonof efficacy and safety between tildrakizumab and secukinumab in the treatment of moderateto-severe plaque psoriasis

CHEN Ning1，FENG Yaoju²， DING Yu1 （1.Dept.of Dermatology，the First Affiliated Hospital of Nanyang Medical College，Henan Nanyang 4730o0，China;2.Dept.of Rheumatology，theFirst Afiliated Hospitalof NanyangMedical College，Henan Nanyang 4730oo，China）

ABSTRACTOBJECTIVETocomparetheeficacyandsafetyoftildrakizumabversussecukinumab inthetreatmentofmoderateto-severe plaque psoriasis.METHODSAretrospectiveanalysiswasconductedon141patientswith moderate-to-severe plaque psoriasistreatedattheFirstAfilatedHospitalofNanyangMedicalCollegefromJanuary2024toApril2025.Accordingtothe treatment regimen，the patients were divided into tildrakizumab group （ n=61 ）and secukinumab group（ n=80 ）. The PASI75，PASI 90，andPASI1OOresponserates，thePsoriasis Areaand Severity Index（PASI）and DermatologyLife Quality Index（DLQI） scores，skinbarierfunction（sebumcontentandstratumcoeum watercontent），inflammatoryfactorlevels[interleuki-17（IL17），tumor necrosis factor ∝ （TNF- α ），and IL-23] before and after treatment，and the incidence of adverse drug reactions during treatment werecompared between thetwo groups.RESULTS After12 weeksof treatment，thePASI75，PASI90，andPASI00 response rates in the tildrakizumab group were significantly higher than those in the secukinumab group （ （P<0.05 ）. After treatment， PASI and DLQI scores as well as serum levels of IL-17，TNF- ∇⋅α∝ ，and IL-23 in both groups were significantly reduced compared to beforetreatmentinthesamegroup；sebumcontentand stratumcorneumwatercontent were significantlyincreasedcomparedto before treatment in the same group （ （P<0.05 ）；the tildrakizumab group showed better results than the secukinumab group （ P< 0.05）.Theoverallincidenceofadversedrugreactionswasalsosignificantlylowerinthetildrakizumabgroupcomparedwiththe secukinumab group （ P<0.05 ）. CONCLUSIONS Compared with secukinumab，tildrakizumab demonstrates superior effcacy in the treatmentof moderate-to-severeplaquepsoriasis，providingimprovedsymptomrelief，enhancedskinbarrerfunction，reduced levels of inflammatory factors，and higher safety.

KEYWORDStildrakizumab；secukinumab；moderate-to-severe plaque psoriasis;； eficacy； safety；biological agent

银屑病是一种以T细胞介导为核心的慢性自身免疫性皮肤病，其中斑块状银屑病是最为常见的亚型，约占全部病例的 80% 。（剩余8860字）